Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other financing activities (2022 - 2023)

Atara Biotherapeutics (ATRA) has disclosed Other financing activities for 2 consecutive years, with -$13000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Other financing activities changed N/A year-over-year to -$13000.0, compared with a TTM value of -$13000.0 through Sep 2024, down 100.04%, and an annual FY2024 reading of -$7000.0, up 46.15% over the prior year.
  • Other financing activities was -$13000.0 for Q2 2023 at Atara Biotherapeutics, down from $30.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $30.8 million in Q4 2022 and bottomed at -$104000.0 in Q1 2022.